[{"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Hevel Modi'in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.", "fullTimeEmployees": 79, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 598000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mali  Zeevi CPA, CPA", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 374000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ella  Sorani Ph.D.", "age": 55, "title": "Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 452000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Holly W. May M.B.A.", "age": 61, "title": "President of BioLineRx USA", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lacey", "title": "Head of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.", "title": "Head of BD & Strategic Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raziel  Fried", "title": "Treasurer & Budgetary Control Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.452, "open": 0.4529, "dayLow": 0.43, "dayHigh": 0.47, "regularMarketPreviousClose": 0.452, "regularMarketOpen": 0.4529, "regularMarketDayLow": 0.43, "regularMarketDayHigh": 0.47, "beta": 0.796, "forwardPE": -1.1921053, "volume": 440941, "regularMarketVolume": 440941, "averageVolume": 296096, "averageVolume10days": 411810, "averageDailyVolume10Day": 411810, "bid": 0.322, "ask": 0.559, "bidSize": 200, "askSize": 200, "marketCap": 37651096, "fiftyTwoWeekLow": 0.39, "fiftyTwoWeekHigh": 1.93, "priceToSalesTrailing12Months": 2.2085345, "fiftyDayAverage": 0.5404, "twoHundredDayAverage": 0.77155, "currency": "USD", "enterpriseValue": 534382400, "profitMargins": -1.7667199, "floatShares": 1092454166, "sharesOutstanding": 79943200, "sharesShort": 621386, "sharesShortPriorMonth": 179216, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0078, "heldPercentInsiders": 0.08537, "heldPercentInstitutions": 0.0539, "shortRatio": 1.94, "shortPercentOfFloat": 0.0078, "impliedSharesOutstanding": 75170304, "bookValue": 0.012, "priceToBook": 37.75, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -30119000, "trailingEps": -0.47, "forwardEps": -0.38, "pegRatio": 0.05, "lastSplitFactor": "1:15", "lastSplitDate": 1563148800, "enterpriseToRevenue": 31.346, "enterpriseToEbitda": -16.154, "52WeekChange": -0.7027027, "SandP52WeekChange": 0.3301804, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BLRX", "underlyingSymbol": "BLRX", "shortName": "BioLineRx Ltd.", "longName": "BioLineRx Ltd.", "firstTradeDateEpochUtc": 1311773400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e62a36f1-05bb-3c53-9aee-d33adfbdf394", "messageBoardId": "finmb_5015080", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.453, "targetHighPrice": 21.0, "targetLowPrice": 2.0, "targetMeanPrice": 9.83, "targetMedianPrice": 6.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 40060000, "totalCashPerShare": 0.033, "ebitda": -33080000, "totalDebt": 31255000, "quickRatio": 1.438, "currentRatio": 1.609, "totalRevenue": 17048000, "debtToEquity": 223.553, "revenuePerShare": 0.24, "returnOnAssets": -0.35229, "returnOnEquity": -1.71937, "freeCashflow": -15807125, "operatingCashflow": -30348000, "grossMargins": 0.64546996, "ebitdaMargins": -1.9403999, "operatingMargins": -1.07046, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]